Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws

Immunovant R&D Day Enabling normal

lives for people with autoimmune disease March 30, 2022 Exhibit 99.1

Forward-looking statements This

presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may,"

"might," "will," "would," "should," "expect," "believe," "estimate," "design," "plan," and other similar expressions are intended to identify

forward-looking statements. Such forward looking statements include Immunovant's plan to start a Phase 3 study for batoclimab in myasthenia gravis (MG) in the first half of calendar year 2022 with an expected data readout in 2024, and

expectations with respect to the safety and monitoring plan and size of the safety database; Immunovant's plan to explore in subsequent study periods follow-on treatment with alternative dosing regimens; Immunovant's plan to develop

batoclimab across a broad range of autoimmune indications; Immunovant's expectations regarding timing, the design and results of clinical trials of its product candidates and indication selections; Immunovant's beliefs regarding its cash

runway, and the potential benefits of batoclimab's unique product attributes. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are

inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: initial results

or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with

regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant's product candidate, including the timing of the commencement of additional clinical trials and resumption of current

trials; Immunovant's scientific approach, clinical trial design, indication selection and general development progress; future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this

presentation; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant's product candidate may not be beneficial to

patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of the ongoing COVID-19 pandemic on Immunovant's clinical development plans and timelines; Immunovant's business is heavily

dependent on the successful development, regulatory approval and commercialization of its sole product candidate, batoclimab; Immunovant is at an early stage in development of batoclimab; and Immunovant will require additional capital to fund its

operations and advance batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant's periodic and other reports filed with the Securities and Exchange Commission (SEC), including in

the section titled "Risk Factors" in Immunovant's most recent Annual Report on Form 10-K, its Form 10-Q filed with the SEC on February 4, 2022, and Immunovant's subsequent filings with the SEC. Any forward-looking statement

speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All trademarks, trade names, service

marks, and copyrights appearing in this presentation are the property of their respective owners.

Q&A housekeeping You may submit

questions through the Q&A function at the bottom of the webcast player. Please see the image here for reference. For Investor Audiences Only

Today's agenda Immunovant and

batoclimab vision and strategy | Pete Salzmann, MD, CEO Immunovant Thyroid Eye Disease an exciting opportunity | Bill Macias, MD, CMO Immunovant Andrea Kossler1, MD, FACS, Stanford University School of Medicine George Kahaly2,

MD, PhD, Johannes Gutenberg University Medical Center Pete Salzmann, MD, CEO Immunovant Myasthenia Gravis a multifaceted disease | Pete Salzmann, MD, CEO Immunovant Katherine Ruzhansky3, MD, MS, Medical University of South Carolina Nicholas

Silvestri4, MD, FAAN, University of Buffalo Warm Autoimmune Hemolytic Anemia opportunity for innovative treatment options | Pete Salzmann, MD, CEO Immunovant David Tucker5 MB ChB, BSc, MD MRCP, FRCPath, Royal Cornwall NHS Hospitals Trust Cholesterol

management what we know | Bill Macias, MD, CMO Immunovant Michael Davidson6, MD, University of Chicago, Pritzker School of Medicine Path forward what comes next | Pete Salzmann, MD, CEO Immunovant Q&A Financial Disclosures: 1. Consultant,

Horizon & Immunovant; Research Funds Horizontal Pharmaceuticals, Viridian Pharmaceuticals, VasaraGen Inc. 2. The Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany (academic institution of George J Kahaly, MD, PhD) has received

research-associated funding from the JGU Medical Faculty, AdvanceCor (Germany), Apitope (Belgium), Berlin-Chemie (Germany), Byondis (The Netherlands), GlycoEra (Switzerland), Horizon (USA), Immunovant (USA), ISAR (Germany), Mediomics (USA), Merck

(Germany), Novartis (USA), Quidel (USA), River Vision (USA), and Roche (Switzerland). GJK consults for GlycoEra, Immunovant, ISAR, Mediomics, Merck, Novartis, Quidel, & VasaraGen (USA). 3. Consultant/advisory board for: Alexion, Argenx,

Ra/UCB, Immunovant; Current grant/research funding from: Alexion, Ra/UCB, Janssen, Myasthenia Gravis Foundation of America, MGNet 4. medical advisory boards and speaker for argenx, UCB, advisory boards for Immunovant, Alexion, Biogen, Roche,

speaker for Strongbridge/Xeris 5. Advisory board honoraria: Roche, Abbvie, Novartis, Consultant, Immunovant 6. Consultant, Immunovant For Investor Audiences Only

Broad development plan enabled by an

exciting mechanism of action, batoclimab's features and a strong balance sheet 01 02 03 Immunovant remains on track to start three pivotal studies in calendar year 20223, and to announce two new indications by August 2022

As of December 31, 2021, per most recent Quarterly Report on Form 10-Q filed with the SEC on February 4, 2022 The assumptions upon which we have based our estimates are routinely evaluated and may be subject to change Three pivotal trials include

myasthenia gravis and two other indications Batoclimab's unique combination of attributes present a potentially significant commercial opportunity across multiple indications in rare autoimmune diseases Immunovant is well-capitalized with

$527M1 in cash expected to fund its broad development plans into calendar year 20252 04 Immunovant plans to initiate a Phase 3 study of batoclimab in Myasthenia Gravis in the first half of calendar year 2022 - topline results

expected in 2024 For Investor Audiences Only

Pete Salzmann, MD Chief Executive

Officer Vision and Strategy

Our vision: Normal lives for people

with autoimmune disease Driven by our core values Love Trailblazing All Voices Bolder, Faster For Investor Audiences Only

Our focus: unmet needs common to many

IgG-mediated autoimmune diseases Improve symptoms and reduce uncertainty More data to guide a proactive approach Significant improvement in Quality of Life Variable time to response for existing treatments (e.g., older non-steroidal

immunosuppressants) Challenging safety profile or logistics (e.g., steroids, IVIg) Reliable treatment options Symptoms may wax and wane Dosing that can be tailored based on the severity and stage of disease Tailored treatment options Desire to feel

like a person, not like a patient Considerations for chronic disease management Simpler route of administration Source: Analysis - Social Listening on MG n=975 / Qualitative research - MG patient journey n=28 / MG Patient Advisory

Council n=6 / MG Patient Quantitative Survey (n=50) For Investor Audiences Only

IgG antibodies mediate autoimmune

disease pathogenesis In many autoimmune diseases, IgG antibodies develop that can recognize and bind to normal tissues1 IgG targets may include cell-surface receptors or circulating proteins IgG autoantibodies trigger a harmful immune responses

resulting in autoimmune symptoms and tissue damage Disease severity may correlate with quantity of pathogenic IgG Thyroid follicle Orbital fibroblast TSHR IgG Normal tissues recognized by IgG autoantibodies in Thyroid Eye Disease1 TSHR IgG Kahaly

GJ. J Clin Endocrinol Metab. 2020;105(12):3704-20 TSHR - thyroid stimulating hormone receptor For Investor Audiences Only

FcRn promotes recycling of IgG

antibodies FcRn Mechanism of Action IgG is taken up into cells in endocytic vesicle FcRn-IgG complexes are sorted from unbound proteins Unbound proteins are trafficked to lysosome for degradation IgG is recycled back into circulation FcRn maintains

levels of IgG in circulation by preventing IgG degradation FcRn extends the half-life of IgG autoantibodies in circulation exacerbating their autoimmune effects FcRn expressed in a variety of cells Blood Endocytic vesicle endosome Lysosome Monocyte

or endothelial cell Key: Serum protein IgG FcRn 1 2 3 4 5 6 For Investor Audiences Only

Batoclimab inhibits FcRn, promoting

IgG degradation Batoclimab Mechanism of Action IgG and batoclimab are taken up into cells in endocytic vesicles Batoclimab binds to FcRn in endosomes FcRn-batoclimab complexes are sorted from unbound proteins Non-receptor bound IgGs are

degraded in lysosomes Batoclimab removes pathogenic antibodies by binding to FcRn and promoting IgG degradation Batoclimab binds to FcRn and reduces the recycling of IgG antibodies As a result, IgG is increasingly delivered to lysosomes for

degradation Relative to older, broad-spectrum immunosuppressants, FcRn inhibitors deliver a more targeted approach to immunomodulation Blood Endocytic vesicle endosome Lysosome Monocyte or endothelial cell Key: Serum protein IgG FcRn 1 2 3 4 5

IMVT-1401 For Investor Audiences Only

Our opportunity: FcRn inhibition has

broad therapeutic potential 17 indications currently announced or in development across the anti-FcRn class ENDOCRINOLOGY Thyroid eye disease RHEUMATOLOGY Primary Sjogrens Syndrome Systemic lupus erythematosus Rheumatoid arthritis

NEUROLOGY Myasthenia Gravis Chronic inflammatory demyelinating polyneuropathy Myositis Autoimmune encephalitis Myelin oligodendrocyte glycoprotein antibody disorders (MOG-antibody disorder) HEMATOLOGY Warm autoimmune hemolytic anemia Hemolytic

disease of the fetus and newborn Idiopathic thrombocytopenic purpura For Investor Audiences Only DERMATOLOGY Bullous pemphigoid Pemphigus foliaceus Pemphigus vulgaris Cutaneous lupus erythematosus RENAL Membranous nephropathy Lupus Nephritis

Potential for anti-FcRn technology

to help a broad range of people impacted by autoimmune disease 2.3M+* PEOPLE Additional, potentially IgG-mediated autoimmune diseases EXPANDED OPPORTUNITY in US and EU INITIAL OPPORTUNITY in US and EU 364K* PEOPLE MG TED wAIHA Estimated number of

people with autoimmune diseases* driven by pathogenic IgG + + + + + + + *Note: Prevalence estimates for autoimmune diseases are illustrative, and are not necessarily indications Immunovant will pursue (supporting data on file at Immunovant). MG:

Myasthenia Gravis; WAIHA: Warm Autoimmune Hemolytic Anemia; TED: Thyroid Eye Disease; Additional IgG-mediated autoimmune diseases include ITP: Idiopathic Thrombocytopenic Purpura; PV: Pemphigus Vulgaris; CIDP: Chronic Inflammatory Demyelinating

Polyneuropathy; BP: Bullous Pemphigoid; PF: Pemphigus Foliaceus; AIE: Autoimmune Encephalitis LGI1+; MOG: Myelin oligodendrocyte glycoprotein antibody disorder; pSS: Primary Sj gren's Syndrome; SLE: Systemic Lupus Erythematosus; HDFN:

Hemolytic Disease of the Fetus and Newborn; RA: Rheumatoid Arthritis; LN: Lupus Nephritis; CLE: Cutaneous Lupus Erythematosus Europe includes all EU countries, the UK and Switzerland For Investor Audiences Only

potentially unique combination of attributes within the anti-FcRn class to address unmet patient needs Novel, fully human, monoclonal antibody inhibiting FcRn-mediated recycling of IgG Batoclimab Tailored dosing to address varying symptom

severity across indications and stage of disease Maximize IgG suppression initially Lower chronic doses when less IgG suppression needed Manage analyte changes Simple, subcutaneous injection that will enable self-administration at home Demonstrated

rapid and deep IgG reduction in studies to-date with subcutaneous injection + + + + + + For Investor Audiences Only

Pioneering anti-FcRn technology to

meaningfully advance the quality of care for people living with autoimmune diseases Novel, fully human, monoclonal antibody inhibiting FcRn-mediated recycling of IgG Batoclimab + + + + + + Intentionally designed to deliver potent IgG reductions via

a standard sub-cutaneous injection for tailored & sustained disease control + For Investor Audiences Only

Pursuing a broad development program

with batoclimab Target Indication Phase 1 Phase 2 Phase 3 Anticipated Milestones Myasthenia Gravis (MG) Phase 3 initiation planned in first half of 2022; top line results expected in 2024 Thyroid Eye Disease (TED) Two of these four indications

will be initiated as pivotal trials for a total of three pivotal trials to begin in 2022 Warm Autoimmune Hemolytic Anemia (WAIHA) Resuming development Indication 4* Preparing to initiate development Indication 5* Preparing to initiate development

*Two new indications to be announced by August 2022 $527M1 in cash expected to fund Immunovant's operating plans into calendar year 2025 1. As of December 31, 2021, per most recent Quarterly Report on Form 10-Q filed with the SEC on

February 4, 2022 For Investor Audiences Only

Pete Salzmann, MD Chief Executive

Officer Thyroid Eye Disease An exciting opportunity Pre-Record

Opportunities in Thyroid Eye Disease

Thyroid eye disease presents with a

variety of clinical symptoms UNDERSTANDING TED: Also referred to as Graves' Ophthalmopathy or Graves' Orbitopathy (GO) due to close temporal relationship with Graves' Disease Progressive disease marked by inflammation that can lead

to fibrosis Clinical features are variable, including but not limited to:1 May become sight-threatening if under-treated2 Beyond IV teprotumumab, disease-modifying treatments are currently limited Davies T. and Burch H.B. Clinical features and

diagnosis of Graves' orbitopathy (ophthalmopathy), UpToDate, 2018. McAlinden C. An overview of thyroid eye disease. Eye and Vision, 2014. Eye bulging ("proptosis") Eye pain Double vision ("diplopia") Swollen/red eyes

Impaired visual ability Bahn, 2010 Figure 1. Patients with Thyroid Eye Disease Panel A shows a 59-year-old woman with excess proptosis, moderate eyelid edema, and erythema with moderate eyelid retraction affecting all four eyelids. Conjunctival

chemosis (edema) and erythema with bilateral edema of the caruncles, with prolapse of the right caruncle, are evident. Panel B shows a 40-year old woman with excess proptosis, minimal bilateral injection, and chemosis with slight erythema of the

eyelids. She also had evidence, on slit-lamp examination, of moderate superior limbic keratoconjunctivitis. For Investor Audiences Only

Patients with active TED report a

substantial impact on their lifestyle and work-life Source: TED Patient Quantitative Survey (n=50) by Immunovant, 2022 46% None of the respondents stated that they make "no lifestyle modifications" around their TED 34% 20% Extent of

lifestyle modifications >75% report the impact of disease on their work-life as very challenging "I cannot bear very bright light which makes it very difficult for me to work on screens" For Investor Audiences Only

Not surprisingly for a heterogeneous

disease, people with TED prioritize different treatment goals Source: TED Patient Quantitative Survey (n=50) by Immunovant, 2022 Most Important Treatment Goals to be Addressed For Investor Audiences Only

Understanding Thyroid Eye

TSHR IGF-1R Anti-TSHR autoantibodies

TED clinical presentation Ocular orbit Thyroid Thyroid follicle Orbital fibroblast Proliferation, differentiation IgG, immunoglobulin g; MOA, mechanism of action; TED, thyroid eye disease; TSHR, thyroid stimulating hormone receptor; IGF-1R insulin

growth factor-1 receptor A. Adapted from: Smith TJ, Heged s L. N Engl J Med. 2016;375(16):1552-1565. Kahaly GJ. J Clin Endocrinol Metab. 2020;105(12):3704-20. T3, T4 Anti-TSHR autoantibodies drive the pathogenesis of both